Insider Transactions in Q4 2025 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,809
-3.4%
|
$112,158
$62.44 P/Share
|
|
Dec 22
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
675
-1.25%
|
$41,850
$62.72 P/Share
|
|
Dec 22
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,177
+2.91%
|
-
|
|
Dec 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,016
-0.71%
|
$62,992
$62.72 P/Share
|
|
Dec 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+1.39%
|
-
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
33,361
-4.12%
|
$2,168,465
$65.45 P/Share
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,530
+1.42%
|
-
|
|
Dec 22
2025
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
805
-1.11%
|
$49,910
$62.72 P/Share
|
|
Dec 22
2025
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,304
+2.94%
|
-
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
71,233
+7.98%
|
$427,398
$6.67 P/Share
|
|
Dec 22
2025
|
Wendell Wierenga Director |
SELL
Open market or private sale
|
Direct |
20,000
-38.14%
|
$1,320,000
$66.14 P/Share
|
|
Dec 22
2025
|
Wendell Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+27.61%
|
$140,000
$7.61 P/Share
|
|
Dec 16
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,200
-1.56%
|
$134,200
$61.24 P/Share
|
|
Dec 16
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+1.54%
|
$22,000
$10.6 P/Share
|
|
Dec 08
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,042
-2.02%
|
$67,730
$65.96 P/Share
|
|
Dec 08
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042
+1.98%
|
$40,638
$39.13 P/Share
|
|
Dec 05
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
52,486
-50.89%
|
$3,411,590
$65.95 P/Share
|
|
Dec 05
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
52,486
+13.78%
|
$1,784,524
$34.41 P/Share
|
|
Dec 03
2025
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,560
-2.25%
|
$101,400
$65.02 P/Share
|
|
Dec 03
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,058
-1.46%
|
$133,770
$65.02 P/Share
|
|
Dec 03
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,368
-2.63%
|
$88,920
$65.02 P/Share
|
|
Dec 03
2025
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,930
-1.67%
|
$385,450
$65.02 P/Share
|
|
Dec 02
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,200
-1.54%
|
$138,600
$63.89 P/Share
|
|
Dec 02
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+1.52%
|
$22,000
$10.6 P/Share
|
|
Dec 02
2025
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
8,750
-10.5%
|
$551,250
$63.9 P/Share
|
|
Dec 02
2025
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+9.5%
|
$87,500
$10.0 P/Share
|
|
Dec 01
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
28,064
-73.77%
|
$1,852,224
$66.72 P/Share
|
|
Dec 01
2025
|
Edward M. Md Kaye Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,064
+32.67%
|
$364,832
$13.33 P/Share
|
|
Dec 01
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
2,150
-10.39%
|
$141,900
$66.8 P/Share
|
|
Nov 19
2025
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
5,000
-17.9%
|
$320,000
$64.73 P/Share
|
|
Nov 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,200
-1.54%
|
$145,200
$66.45 P/Share
|
|
Nov 18
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+1.52%
|
$22,000
$10.6 P/Share
|
|
Nov 14
2025
|
Jeffrey Hessekiel Chief Legal & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,297
+50.0%
|
-
|
|
Nov 11
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
5,175
-34.15%
|
$336,375
$65.08 P/Share
|
|
Nov 11
2025
|
Edward M. Md Kaye Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,175
+25.46%
|
$46,575
$9.66 P/Share
|
|
Nov 05
2025
|
Robert I Blum President & CEO |
SELL
Bona fide gift
|
Direct |
2,000
-0.56%
|
-
|
|
Nov 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,295
-1.61%
|
$135,405
$59.55 P/Share
|
|
Nov 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,295
+1.58%
|
$22,950
$10.6 P/Share
|
|
Oct 30
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$310,000
$62.86 P/Share
|
|
Oct 27
2025
|
Wendell Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,375
-11.88%
|
$253,750
$58.68 P/Share
|
|
Oct 27
2025
|
Wendell Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+10.62%
|
$43,750
$10.0 P/Share
|
|
Oct 21
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,105
-1.48%
|
$122,090
$58.22 P/Share
|
|
Oct 21
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,105
+1.45%
|
$21,050
$10.6 P/Share
|
|
Oct 16
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.36%
|
$300,000
$60.03 P/Share
|
|
Oct 15
2025
|
Wendell Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.3%
|
$6,138
$62.8 P/Share
|
|
Oct 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+1.96%
|
$12,338
$62.8 P/Share
|
|
Oct 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+0.45%
|
$20,956
$62.8 P/Share
|
|
Oct 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+0.95%
|
$12,338
$62.8 P/Share
|
|
Oct 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.32%
|
$6,138
$62.8 P/Share
|
|
Oct 07
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$120,000
$60.56 P/Share
|